Arbutus Biopharma (ABUS) Income from Continuing Operations (2013 - 2026)
Arbutus Biopharma (ABUS) posted quarterly Income from Continuing Operations of 169700000.0 for Q1 2026, up 791.81% year-on-year from 19028803.25 in Q1 2025, and up 3515.86% on a QoQ basis from 4968000.0 in Q4 2025.
Arbutus Biopharma (ABUS) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Arbutus Biopharma (ABUS) has reported Income from Continuing Operations for 14 consecutive years, with 169700000.0 the latest figure, recorded in Q1 2026.
- Quarterly Income from Continuing Operations rose 791.81% year-over-year to 169700000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 159504000.0 (up 308.22% YoY) and the FY2025 annual result came in at 215482000.0, down 208.18% from the prior year.
- Income from Continuing Operations improved to 169700000.0 in Q1 2026 per ABUS's latest filing, from 4968000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for ABUS reached as high as 169700000.0 in Q1 2026 and fell as low as 24530000.0 in Q1 2025.
- A 5-year average of 4552294.12 and a median of 17094000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations sank 36.38% — and 2026, when it surged 791.81%.
- Year by year, Income from Continuing Operations stood at 21932000.0 in 2022, then gained by 11.95% to 19312000.0 in 2023, then jumped by 35.28% to 12499000.0 in 2024, then surged by 60.25% to 4968000.0 in 2025, then surged by 3515.86% to 169700000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 169700000.0, 4968000.0, and 7730000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - | 169.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 169.70 Mn |
| Dec 31, 2025 | -4.97 Mn |
| Sep 30, 2025 | -7.73 Mn |
| Jun 30, 2025 | 2.50 Mn |
| Mar 31, 2025 | -24.53 Mn |
| Dec 31, 2024 | -12.50 Mn |
| Sep 30, 2024 | -19.72 Mn |
| Jun 30, 2024 | -19.85 Mn |
| Mar 31, 2024 | -17.99 Mn |
| Dec 31, 2023 | -19.31 Mn |
| Sep 30, 2023 | -20.10 Mn |
| Jun 30, 2023 | -17.09 Mn |
| Mar 31, 2023 | -16.34 Mn |
| Dec 31, 2022 | -21.93 Mn |
| Sep 30, 2022 | -17.57 Mn |
| Jun 30, 2022 | -14.19 Mn |
| Mar 31, 2022 | -15.77 Mn |
| Dec 31, 2021 | -21.32 Mn |
| Sep 30, 2021 | -19.16 Mn |
| Jun 30, 2021 | -19.39 Mn |